Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities
High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specifi...
Published in: | Nature Immunology |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
Nature Publishing Group US
2023
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232372/ http://www.ncbi.nlm.nih.gov/pubmed/37248417 https://doi.org/10.1038/s41590-023-01508-y |
id |
ftpubmed:oai:pubmedcentral.nih.gov:10232372 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:10232372 2023-06-18T03:40:37+02:00 Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities Zhang, Wuji Kedzierski, Lukasz Chua, Brendon Y. Mayo, Mark Lonzi, Claire Rigas, Vanessa Middleton, Bianca F. McQuilten, Hayley A. Rowntree, Louise C. Allen, Lilith F. Purcell, Ruth A. Tan, Hyon-Xhi Petersen, Jan Chaurasia, Priyanka Mordant, Francesca Pogorelyy, Mikhail V. Minervina, Anastasia A. Crawford, Jeremy Chase Perkins, Griffith B. Zhang, Eva Gras, Stephanie Clemens, E. Bridie Juno, Jennifer A. Audsley, Jennifer Khoury, David S. Holmes, Natasha E. Thevarajan, Irani Subbarao, Kanta Krammer, Florian Cheng, Allen C. Davenport, Miles P. Grubor-Bauk, Branka Coates, P. Toby Christensen, Britt Thomas, Paul G. Wheatley, Adam K. Kent, Stephen J. Rossjohn, Jamie Chung, Amy W. Boffa, John Miller, Adrian Lynar, Sarah Nelson, Jane Nguyen, Thi H. O. Davies, Jane Kedzierska, Katherine 2023-05-29 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232372/ http://www.ncbi.nlm.nih.gov/pubmed/37248417 https://doi.org/10.1038/s41590-023-01508-y en eng Nature Publishing Group US http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232372/ http://www.ncbi.nlm.nih.gov/pubmed/37248417 http://dx.doi.org/10.1038/s41590-023-01508-y © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . Nat Immunol Article Text 2023 ftpubmed https://doi.org/10.1038/s41590-023-01508-y 2023-06-04T01:33:12Z High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specific B cells, and CD4(+) and CD8(+) T cells. In First Nations participants, RBD IgG antibody titers were correlated with body mass index and negatively correlated with age. Reduced RBD antibodies, spike-specific B cells and follicular helper T cells were found in vaccinated participants with chronic conditions (diabetes, renal disease) and were strongly associated with altered glycosylation of IgG and increased interleukin-18 levels in the plasma. These immune perturbations were also found in non-Indigenous people with comorbidities, indicating that they were related to comorbidities rather than ethnicity. However, our study is of a great importance to First Nations peoples who have disproportionate rates of chronic comorbidities and provides evidence of robust immune responses after COVID-19 vaccination in Indigenous people. Text First Nations PubMed Central (PMC) Nature Immunology 24 6 966 978 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Article |
spellingShingle |
Article Zhang, Wuji Kedzierski, Lukasz Chua, Brendon Y. Mayo, Mark Lonzi, Claire Rigas, Vanessa Middleton, Bianca F. McQuilten, Hayley A. Rowntree, Louise C. Allen, Lilith F. Purcell, Ruth A. Tan, Hyon-Xhi Petersen, Jan Chaurasia, Priyanka Mordant, Francesca Pogorelyy, Mikhail V. Minervina, Anastasia A. Crawford, Jeremy Chase Perkins, Griffith B. Zhang, Eva Gras, Stephanie Clemens, E. Bridie Juno, Jennifer A. Audsley, Jennifer Khoury, David S. Holmes, Natasha E. Thevarajan, Irani Subbarao, Kanta Krammer, Florian Cheng, Allen C. Davenport, Miles P. Grubor-Bauk, Branka Coates, P. Toby Christensen, Britt Thomas, Paul G. Wheatley, Adam K. Kent, Stephen J. Rossjohn, Jamie Chung, Amy W. Boffa, John Miller, Adrian Lynar, Sarah Nelson, Jane Nguyen, Thi H. O. Davies, Jane Kedzierska, Katherine Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities |
topic_facet |
Article |
description |
High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specific B cells, and CD4(+) and CD8(+) T cells. In First Nations participants, RBD IgG antibody titers were correlated with body mass index and negatively correlated with age. Reduced RBD antibodies, spike-specific B cells and follicular helper T cells were found in vaccinated participants with chronic conditions (diabetes, renal disease) and were strongly associated with altered glycosylation of IgG and increased interleukin-18 levels in the plasma. These immune perturbations were also found in non-Indigenous people with comorbidities, indicating that they were related to comorbidities rather than ethnicity. However, our study is of a great importance to First Nations peoples who have disproportionate rates of chronic comorbidities and provides evidence of robust immune responses after COVID-19 vaccination in Indigenous people. |
format |
Text |
author |
Zhang, Wuji Kedzierski, Lukasz Chua, Brendon Y. Mayo, Mark Lonzi, Claire Rigas, Vanessa Middleton, Bianca F. McQuilten, Hayley A. Rowntree, Louise C. Allen, Lilith F. Purcell, Ruth A. Tan, Hyon-Xhi Petersen, Jan Chaurasia, Priyanka Mordant, Francesca Pogorelyy, Mikhail V. Minervina, Anastasia A. Crawford, Jeremy Chase Perkins, Griffith B. Zhang, Eva Gras, Stephanie Clemens, E. Bridie Juno, Jennifer A. Audsley, Jennifer Khoury, David S. Holmes, Natasha E. Thevarajan, Irani Subbarao, Kanta Krammer, Florian Cheng, Allen C. Davenport, Miles P. Grubor-Bauk, Branka Coates, P. Toby Christensen, Britt Thomas, Paul G. Wheatley, Adam K. Kent, Stephen J. Rossjohn, Jamie Chung, Amy W. Boffa, John Miller, Adrian Lynar, Sarah Nelson, Jane Nguyen, Thi H. O. Davies, Jane Kedzierska, Katherine |
author_facet |
Zhang, Wuji Kedzierski, Lukasz Chua, Brendon Y. Mayo, Mark Lonzi, Claire Rigas, Vanessa Middleton, Bianca F. McQuilten, Hayley A. Rowntree, Louise C. Allen, Lilith F. Purcell, Ruth A. Tan, Hyon-Xhi Petersen, Jan Chaurasia, Priyanka Mordant, Francesca Pogorelyy, Mikhail V. Minervina, Anastasia A. Crawford, Jeremy Chase Perkins, Griffith B. Zhang, Eva Gras, Stephanie Clemens, E. Bridie Juno, Jennifer A. Audsley, Jennifer Khoury, David S. Holmes, Natasha E. Thevarajan, Irani Subbarao, Kanta Krammer, Florian Cheng, Allen C. Davenport, Miles P. Grubor-Bauk, Branka Coates, P. Toby Christensen, Britt Thomas, Paul G. Wheatley, Adam K. Kent, Stephen J. Rossjohn, Jamie Chung, Amy W. Boffa, John Miller, Adrian Lynar, Sarah Nelson, Jane Nguyen, Thi H. O. Davies, Jane Kedzierska, Katherine |
author_sort |
Zhang, Wuji |
title |
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities |
title_short |
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities |
title_full |
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities |
title_fullStr |
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities |
title_full_unstemmed |
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities |
title_sort |
robust and prototypical immune responses toward covid-19 vaccine in first nations peoples are impacted by comorbidities |
publisher |
Nature Publishing Group US |
publishDate |
2023 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232372/ http://www.ncbi.nlm.nih.gov/pubmed/37248417 https://doi.org/10.1038/s41590-023-01508-y |
genre |
First Nations |
genre_facet |
First Nations |
op_source |
Nat Immunol |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232372/ http://www.ncbi.nlm.nih.gov/pubmed/37248417 http://dx.doi.org/10.1038/s41590-023-01508-y |
op_rights |
© The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
op_doi |
https://doi.org/10.1038/s41590-023-01508-y |
container_title |
Nature Immunology |
container_volume |
24 |
container_issue |
6 |
container_start_page |
966 |
op_container_end_page |
978 |
_version_ |
1769005792415973376 |